RTS signs vendor financing agreement with MAKO Surgical

Relational Technology Solutions (RTS), the fifth largest independent finance company in the U.S., today announced that it has entered into a vendor financing agreement with MAKO Surgical Corp. (NASDAQ:MAKO), a medical device company that markets its surgeon-interactive robotic arm system, and proprietary implants, for a minimally invasive orthopedic knee procedure called MAKOplasty®. Under the arrangement, hospitals will be able to fund equipment purchases of MAKO’s RIO® robotic arm system through monthly operating lease payments through RTS.

“This agreement with RTS will provide our customers, ranging from critical access hospitals in rural communities to multi-site facilities located in major metropolitan areas, with expanded financing options critical in today’s economic climate,” said Steve J. Nunes, senior vice president of Sales and Marketing at MAKO Surgical Corp.

“MAKO’s solutions not only improve patient care, but also help hospitals and doctors grow their services and attract more patients,” said Daniel Krajewski, vice president of Vendor Financial Services at RTS. “We look forward to providing healthcare organizations with the ability to fund acquisitions of the RIO® system through a variety of lease arrangements, which will allow them to match revenue growth with new technology costs.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The future of UK life sciences starts in the West Midlands